Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Factors Affecting Disease-Free Status of Differentiated Thyroid Carcinoma Patients

  • Thamnirat, Kanungnij (Nuclear Medicine Division, Department of Radiology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University) ;
  • Utamakul, Chirawat (Nuclear Medicine Division, Department of Radiology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University) ;
  • Chamroonrat, Wichana (Nuclear Medicine Division, Department of Radiology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University) ;
  • Kositwattanarerk, Arpakorn (Nuclear Medicine Division, Department of Radiology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University) ;
  • Anongpornjossakul, Yoch (Nuclear Medicine Division, Department of Radiology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University) ;
  • Sritara, Chanika (Nuclear Medicine Division, Department of Radiology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University)
  • Published : 2015.02.25
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: The study aim was to assess factors that impact on the outcome of radioiodine therapy in patients diagnosed with differentiated thyroid carcinoma (DTC). Materials and Methods: We performed a retrospective cohort study on 256 patients with DTC who underwent thyroidectomy and received radioiodine therapy during December 2003 to January 2012. All patients were followed up for at least 1 year. They were considered diseasefree by the criteria of the revised American Thyroid Association Management Guideline for Patients with Thyroid nodules and DTC (ATA guideline 2009). Results: On Cox univariate analysis, factors associated with disease-free status were age<45, stage I tumor, low risk group by histopathology, unifocal tumor involvement, stimulated serum Tg level at 1st dose of radioiodine therapy and no distant metastasis from 1st post-treatment WBS (post RxWBS). On multivariate analysis, stage I tumor and stimulated serum Tg level at 1st dose of radioiodine therapy < 30 ng/mL were the significant prognostic factors that increased disease-free rate by 1.73 times and 2.60 times, respectively (P-value <0.05). Conclusions: Factors affecting the outcome of radioiodine therapy in our study were age, stage, risk of recurrence by histopathology, unifocal tumor involvement and 1st postRxWBS findings. From these factors, stage I tumor and stimulated serum Tg level at 1st dose of radioiodine therapy were independent prognostic factors that substantial increase the disease-free rate.

Keywords

References

  1. Byar DP, Green SB, Dor P, et al (1979). A prognostic index for thyroid carcinoma: a study of the E.O.R.T.C. Thyroid cancer cooperative group. Eur J Cancer, 15, 1033-41. https://doi.org/10.1016/0014-2964(79)90291-3
  2. Cooper DS, Doherty GM, Haugen BR, et al (2009). Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid, 19, 1167-214. https://doi.org/10.1089/thy.2009.0110
  3. Davis NL, Bugis SP, McGregor GI, Germann E (1995). An evaluation of prognostic scoring systems in patients with follicular thyroid cancer. Am J Surg, 170, 476-80. https://doi.org/10.1016/S0002-9610(99)80333-X
  4. Durante C, Haddy N, Baudin E, et al (2006). Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab, 91, 2892-9. https://doi.org/10.1210/jc.2005-2838
  5. D'Avanzo A, Ituarte P, Treseler P, et al (2004). Prognostic scoring systems in patients with follicular thyroid cancer: a comparison of different staging systems in predicting the patient outcome, Thyroid, 14, 453-8. https://doi.org/10.1089/105072504323150778
  6. Falvo L, Catania A, D'Andrea V, et al (2005). Prognostic importance of histologic vascular invasion in papillary thyroid carcinoma. Ann Surg, 241, 640-6. https://doi.org/10.1097/01.sla.0000157317.60536.08
  7. Gemsenjager E, Heitz PU, Seifert B, et al (2001). Differentiated thyroid carcinoma, Follow-up of 264 patients from one institution for up to 25 years. Swiss Med Wkly, 131, 157-63.
  8. Hasbek Z, Turgut B, Kilicli F, et al (2014). Importance of postoperative stimulated thyroglobulin level at the time of 131i ablation therapy for differentiated thyroid cancer. Asian Pac J Cancer Prev, 15, 2523-7. https://doi.org/10.7314/APJCP.2014.15.6.2523
  9. Hay ID, Bergstralh EJ, Goellner JR, et al (1993). Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery, 114, 1050-7.
  10. Heemstra KA, Liu YY, Stokkel M, et al (2007). Serum thyroglobulin concentrations predict disease-free remission and death in differentiated thyroid carcinoma. Clin Endocrinol, 66, 58-64.
  11. Kim TY, Hong SJ, Kim JM, et al (2008). Prognostic parameters for recurrence of papillary thyroid microcarcinoma. BMC Cancer, 8, 296. https://doi.org/10.1186/1471-2407-8-296
  12. Khayamzadeh M, Khayamzadeh M, Tadayon N, et al (2011). Survival of thyroid cancer and social determinants in Iran, 2001-2005, Asian Pacific J Cancer Prev, 12, 95-8.
  13. Lang BH, Lo CY, Chan WF, et al (2006). Prognostic factors in papillary and follicular thyroid carcinoma: their implications for cancer staging. Ann Surg Onc, 14, 730-8.
  14. Lin JD, Kao PF, Chao TC (1998). The effects of radioactive iodine in thyroid remnant ablation of well differntiated thyroid carcinoma. Br J Radiol, 71, 307-13. https://doi.org/10.1259/bjr.71.843.9616241
  15. McConahey WM, Hay ID, Woolner LB, et al (1986). Papillary thyroid cancer treated at the Mayo Clinic 1946 through 1970: initial manifestations, pathologic findings, therapy and outcomes. Mayo Clinic Proc, 61, 978-96. https://doi.org/10.1016/S0025-6196(12)62641-X
  16. Sautter-Bihl ML, Raub J, Hetzel-Sesterheim M, Heinze HG (2001). Differentiated thyroid cancer: prognostic factors and influence of treatment on the outcome in 441 patients. Strahlenther Onkol, 177, 125-31. https://doi.org/10.1007/PL00002392
  17. Sobin LH, Wittekind CH (2002). UICC: TNM Classification of Malignant Tumors 6th ed. NewYork: Wiley-Liss.
  18. Sritara C, Taeshineetanakul P, Kositwatanarerk A, et al (2008) Cutoff Point for Serum TgAb by ICMA Technique in Patients with Differentiated Thyroid Carcinoma (DTC). http://www2.ra.mahidol.ac./rar/infor_reserch_rama/Annual %20Absrtract/MeetInter2008.pdf.
  19. Toniato A, Boschin I, Casara D, et al (2008). Papillary thyroid carcinoma: factors influencing recurrence and survival. Ann Surg Oncol, 15, 1518-22. https://doi.org/10.1245/s10434-008-9859-4
  20. Tubiana M, Schlumberger M, Rougier P, et al (1985). Long-term results and prognostic factors in patients with differentiated thyroid carcinoma. Cancer, 55, 794-804. https://doi.org/10.1002/1097-0142(19850215)55:4<794::AID-CNCR2820550418>3.0.CO;2-Z
  21. Verburg FA, de Keizer B, Lips CJ, et al (2005). Prognostic significance of successful ablation with radioiodine of differentiated thyroid cancer patients. Eur J Endocrinol, 152, 33-7. https://doi.org/10.1530/eje.1.01819
  22. Yang Y, Li Q, Guo L, et al (2011). A Retrospective Analysis of Thyroid Cancer in China. Asian Pac J Cancer Prev, 12, 2245-9.
  23. Zaman MU, Fatima N, Padhy, et al (2013). Controversies about radioactive iodine-131 remnant ablation in low risk thyroid cancers: are we near a consensus? Asian Pac J Cancer Prev, 14, 6209-13. https://doi.org/10.7314/APJCP.2013.14.11.6209
  24. Zaman MU, Fatima N, Sajjad Z, et al (2012). Threshold primary tumour sizes for nodal and distant metastases in papillary and follicular thyroid cancers. Asian Pac J Cancer Prev, 13, 2473-6. https://doi.org/10.7314/APJCP.2012.13.6.2473

Cited by

  1. Hybrid Imaging in Oncology vol.16, pp.14, 2015, https://doi.org/10.7314/APJCP.2015.16.14.5599